Author highlights ImmunityBio's durable complete responses in Waldenstrom Non-Hodgkin Lymphoma patients and frames IBRX as a long-term buy-and-hold.
IBRX — LONG The author points to ImmunityBio's announcement that four Waldenstrom Non-Hodgkin Lymphoma patients enrolled remain in clinical disease control, with two showing durable complete remission at 7 and 15 months after only eight initial immunotherapy doses. He argues this is an 'incredible buy and hold' because patients and society would pay any cost to avoid chemotherapy. The stated catalyst is the durable complete response data; the author supplies no explicit risk beyond his personal conviction.
Incredible buy and hold, I’m older and know we’ll pay any cost price to fix something like this without Chemotherapy
This Reddit post, published January 16, 2026, features u/Historical_Flow3890 discussing IBRX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Historical_Flow3890 · Tickers: IBRX